INSULET CORP (PODD) Risk Factors
Health CareLatest 10-K filed Feb 18, 2026Source: SEC EDGAR
WealthWire extracted and classified 42 risk factors from INSULET CORP’s latest SEC filing, mapping each to a standardized risk taxonomy so they can be compared across every company and sector. The breakdown below shows how those disclosures distribute across risk categories.
Legal & regulatory
10 factorsOperations & people
8 factorsTechnology
7 factorsMarket & business
7 factorsFinancial
5 factorsHealthcare & life sciences
3 factorsOther
1 factorsESG & reputation
1 factorsRecent key developments
Concrete developments — dated events, named agreements and instruments, legal proceedings — that INSULET CORP surfaced in its latest filing.
- Substantially all commercialized Drug Delivery revenue consists of sales of a customized product for Amgen's Neulasta Onpro kit under an agreement expiring December 2028December 2028
- Agreement with Glooko expires in December 2026December 2026
- BIS announced an investigation into imports of personal protective equipment, medical consumables, and medical equipment including insulin pumps under Section 232 of the Trade Expansion Act of 1962
- EU AI Act is taking effect in stages through August 2026August 2026
- In 2025, changes occurred in key leadership roles, including Chief Executive Officer and Chief Financial Officer2025
- In 2023, ongoing adoption of GLP-1 drugs in diabetes and news surrounding expansion of use in obesity led to speculation regarding impact on insulin therapy market, which negatively impacted stock prices of companies in the medical device industry, including ours2023
Go deeper on PODD
This page shows the category breakdown of the latest filing. The WealthWire API and dashboard add the full risk-factor text, multi-year trends, sector comparisons, and CSV export — for PODD and every other S&P 500 company.